Anti-CD19 [4G7]
Invented at
- Datasheet
- References (0)
- Inventor Info
Info
| Catalogue Number | 153512 |
| Applications | ELISA FACS IHC WB |
| Antigen/Gene or Protein Targets | CD19 |
| Synonyms | B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12 |
| Reactivity | Human |
| Relevance |
CD19 assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas.Since 2011 treatments targeting CD19 have begun to enter trials. Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers. However, it is now emerging that the protein plays an active role in driving the growth of these cancers, most intriguingly by stabilizing the concentrations of the myc oncoprotein. This suggests that CD19 and its downstream signaling may be a more attractive therapeutic target than originally thought. CD19 has also been implicated in autoimmune diseases and may be a useful treatment target. |
| Host | Mouse |
| Immunogen | CD19 |
| Subclass | IgG1 |
| Notes | Purified via protein G |
| Research Area | Cancer, Cell Type or Organelle Marker, Cell Signaling & Signal Transduction, Immunology |
References
There are 0 reference entries for this reagent.
References: 0 entry
There is no reference for this reagent yet, feel free to use the button below to suggest one.
Add a reference
References: 0 entry
There is no reference for this reagent yet, feel free to use the button below to suggest one.
Add a reference